Displaying 41 (all) recruiting clinical trials.
-
A Phase 2 Open-Label Multi-Center Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible fo
This study looks at two treatments (TAR-200 + IV cetrelimab versus IV cetrelimab alone) for a specific kind of bladder cancer (muscle-invasive bladder cancer unsuitable for ...